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ABSTRACT:
Caspase-2 is ubiquitously expressed and the most evolutionarily conserved 
mammalian caspase. It can be activated by a range of death stimuli prior to Bax 
activation and the occurrence of apoptotic mitochondrial dysfunctions. Caspase-2 
has also been reported to exert tumour suppressor function in vivo. The full length 
TAp73alpha isoform is found up-regulated in various tumour types, and is reported 
in a cell-type specific manner to repress drug-induced apoptosis. Here, we report 
that TAp73alpha represses caspase-2 enzymatic activity and by this means reduce 
caspase-2 induced Bax activation, loss of mitochondrial transmembrane potential 
and resulting apoptosis. The inhibitory effect on caspase-2 requires the presence of 
the DNA binding domain and SAM domain region of TAp73alpha. In conclusion, the 
ability of TAp73alpha to act as an inhibitor of caspase-2-induced cell death together 
with its up-regulation in certain tumour types strengthen the potential oncogenic 
activities for this protein.
INTRODUCTION
The transcription factor p73 is a multi-functional 
protein that belongs to the p53 family of proteins. Indeed, 
p73 is able to regulate cell cycle arrest [1], apoptosis [2], 
differentiation [3] and development [4]. The p73 protein 
contains a NH2-terminal transactivation (TA) domain, a 
highly conserved core DNA-binding domain (DBD), and 
a COOH-terminal oligomerization domain [5-6]. The P73 
gene has two alternative promoters (p1 and p2) and gives 
rise to a vast number of isoforms due to the use of these 
promoters and from alternative splicing at the COOH-
terminal region. The two alternative promoters located at 
the NH2-terminal region generate either transactivation 
(TA)  competent  or  TA  deficient  (deltaN)  primary 
transcripts of p73. Alternative splicing of each of these 
primary p73 transcripts can theoretically generate nine 
different COOH-terminal isoform variants (alpha, beta, 
gamma, delta, epsilon, theta, zeta, eta and eta1) [7]. Among 
these isoforms, TAp73alpha and TAp73beta are the two 
main expressed isoforms in human cells. TAp73alpha 
is the longest isoform, comprise an extended COOH-
terminus including a sterile alpha motif (SAM) region. 
TAp73beta is a shorter isoform, and lacks the extreme 
COOH-terminal region and SAM domain [8]. p73 and its 
family member p53 share both structural and functional 
properties [9-11]. Nevertheless, some key differences 
between the two proteins do exist, for example, the 
novel structural protein NSP 5a3a can induce apoptosis 
via p73, independent of p53 [12]. Moreover, P73 gene 
mutations are seldom noticed in tumours as compared 
with P53 gene mutations [13]. However, mice selectively 
devoid of the TAp73 isoforms (TAp73 null mice) do show 
increased incidence of spontaneous tumors [14]. On the 
other hand, increased TAp73alpha expression levels 
has been noticed in certain cancers like, cervical cancer 
[7], medulloblastoma [15], B-cell chronic lymphocytic 
leukaemia [16], ovarian carcinomas [17], gastric 
adenocarcinoma [18], bladder cancer [19] and thyroid 
cancer [20]. In some tumour cell lines, increased levels of 
TAp73alpha were detected after various drug treatments, 
e.g. etoposide (VP16; Vepesid®), and camptothecin 
[21]. We previously reported that TAp73alpha inhibits 
drug (i.e. VP16, cisplatin and staurosporine)-induced 
apoptosis in small cell lung carcinoma (SCLC) cells. The 
anti-apoptotic effect is exerted upstream of mitochondrial Oncotarget 2011; 2:   1145 - 1154 1146 www.impactjournals.com/oncotarget
outer membrane permeabilization (MOMP), at the level 
of Bax activation [22].
Interestingly, caspase-2, one of the ubiquitously 
expressed and the most evolutionarily conserved 
mammalian caspase, can be activated before the MOMP that 
occurs during apoptosis induced by a range of death stimuli 
[23-33]. In fact, caspase-2 has long been recognized as an 
important protein in the regulation of apoptosis [30, 34]. 
Caspase-2 contains a caspase activation and recruitment 
domain (CARD), and biochemical studies indicate that 
the primary event required for caspase-2 activation is 
CARD-dependent dimerization. Recruitment of caspase-2 
to activation complexes, such as the PIDDosome, induce 
caspase-2 proximity and hence, its activation [35-36]. 
Worth to notice is that caspase-2 over-expression per se 
leads to CARD-mediated dimerization, enzyme activation 
and induction of apoptotic cell death [35, 37]. Active 
caspase-2 was found to engage mitochondria by directly 
cleaving full-length Bid to activated tBid and promoting 
Bax translocation to the mitochondria [27, 30, 38].
Caspases-3, -7 and -9 have been shown to be 
susceptible to inhibition by members of the inhibitors 
of apoptosis (IAP) family [39]. Despite the fact that 
caspase-2 was the second caspase to be cloned in 1992, 
to date no natural caspase-2 inhibitors have been reported 
(with the exception of some baculoviral proteins, e.g. 
p35 and p49) [37]. Since TAp73alpha has been reported 
to exert its anti-apoptotic effects in SCLC cells upstream 
of Bax activation, this inspired us to investigate whether 
TAp73alpha could modulate cell death mediated by 
caspase-2. In the present study we reveal that TAp73alpha 
is able to repress caspase-2 induced apoptosis in SCLC 
NCI-H82 cells, through inhibition of caspase-2 enzymatic 
activity. Upon TAp73alpha expression, caspase-2 induced 
Bax activation, loss of mitochondrial membrane potential 
and consequent cell death were found reduced. Moreover, 
we report that both the DBD and the SAM domain of 
Figure 1: TAp73alpha inhibits apoptosis induced by caspase-2 over-expression in SCLC NCI-H82 cells. SCLC NCI-H82 
cells (Figure 1A-D) were co-transfected with EGFP together with either an empty (control) vector or plasmids encoding TAp73alpha, 
TAp73beta and/or caspase-2. Twenty-four hours post-transfection, cells were fixed in 4% PFA, stained with Hoechst and scored under 
a fluorescence microscope as percentage of EGFP expressing cells displaying condensed or fragmented nuclei. Three hundred EGFP 
transfected cells were analyzed and each experiment was repeated three times. Figures are mean + SD of three independent experiments, 
where ***p-value <0.001, **p-value <0.01
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TAp73alpha are required for its anti-apoptotic effects on 
caspase-2 induced cell death.
RESULTS
TAp73alpha inhibits apoptosis induced by 
caspase-2 over-expression in SCLC NCI-H82 cells
Caspase-2 processing and activation occurs rapidly 
in response to both intrinsic and extrinsic cell death 
signalling [40-42]. In turn, active caspase-2 promotes 
Bax translocation to the mitochondria [27]. Moreover, the 
ability of over-expressed caspase-2 to promote apoptosis 
is established [34, 43]. We have previously shown that 
full-length TAp73alpha represses drug-induced apoptosis 
in SCLC cells, upstream of the mitochondria at the level 
of Bax activation [22, 44]. To test whether caspase-2 over-
expression induces apoptosis in SCLC NCI-H82 cells 
and whether TAp73alpha can exert a repressive effect 
on caspase-2 induced cell death, apoptosis assays were 
performed. NCI-H82 SCLC cells were co-transfected 
with EGFP together with either an empty (control) vector 
or plasmids encoding TAp73alpha, TAp73beta and/or 
caspase-2. Twenty-four hours post-transfection, cells 
were fixed with 4% PFA, stained with Hoechst and scored 
under a fluorescence microscope as percentage of EGFP 
expressing cells displaying apoptotic nuclei. In NCI-H82 
cells, caspase-2 expression induced a robust apoptotic 
cell death (Fig. 1A, 1B and 1D), whereas TAp73alpha 
expression only caused small increase in apoptosis as 
compared to the basal level (Fig. 1A and D). Remarkably, 
co-expression of TAp73alpha together with caspase-2 led 
to a significant decrease in the percentage of apoptotic 
cells as compared to cells transfected with caspase-2 alone 
(Fig. 1A, 1C and D). On the other hand, co-expression 
with TAp73beta significantly promoted caspase-2 induced 
apoptosis (Fig. 1B). Increasing the ratio of TAp73alpha 
to caspase-2 expression decreased caspase-2 induced 
apoptosis in a dose dependent manner (Fig. 1D). Hence, 
caspase-2 over-expression per se can induce apoptosis 
in SCLC NCI-H82 cells, an event that can be prevented 
by the simultaneous co-expression of anti-apoptotic 
TAp73alpha.
TAp73alpha expression inhibits caspase-2 activity
Thereafter, we investigated whether the protective 
effect of TAp73alpha on caspase-2 induced apoptosis 
could be mediated by direct physical protein-protein 
interaction. Hence, co-immunoprecipitation experiments 
were performed, but no physical interaction between 
these two proteins could be detected. Despite the apparent 
lack of protein-protein interaction, we speculated that 
TAp73alpha might affect the actual enzymatic activity 
of caspase-2. NCI-H82 cells were transfected with 
TAp73alpha, caspase-2 and/or empty expression vectors, 
and caspase-2 activity was monitored. The enzyme activity 
of caspase-2 (VDVADase activity) was evaluated as the 
release of AMC from the substrate Ac-VDVAD-AMC 
(Ac-Val-Asp-Val-Ala-Asp-7-amino-4-methylcoumarin) 
[28]. As previously reported in other cell types, caspase-2 
over-expression lead to increased VDVADase activity 
in NCI-H82 cells (Fig. 2). TAp73alpha over-expression 
caused a small increase in caspase-2 activity, compared 
to the mock vector transfected cells. Interestingly, co-
expression  of  TAp73alpha  with  caspase-2  significantly 
prevented caspase-2 induced VDVADase activity in 
NCI-H82 cells (Fig. 2). Altogether these data indicate 
that TAp73alpha is able to inhibit the enzyme activity of 
caspase-2 in SCLC NCI-H82 cells.
TAp73alpha prevents caspase-2 induced 
mitochondrial dysfunction in SCLC NCI-H82 
cells
Fully processed and active caspase-2 can permeabilize 
the outer mitochondrial membrane and cause cytochrome c 
release [33, 45], which activates the apoptotic cascade 
[28]. We have shown that TAp73alpha is able to prevent 
VP16-induced loss of mitochondrial membrane potential 
in SCLC cells [22, 44]. To explore whether the protective 
effect of TAp73alpha over-expression on caspase-2 
induced apoptosis involve repression of mitochondrial 
dysfunction, the mitochondrial transmembrane potential 
was investigated. 
NCI-H82 cells were co-transfected with EGFP 
together with either an empty (control) vector or plasmids 
Figure 2: TAp73alpha expression inhibits caspase-2 
activity.  SCLC NCI-H82 cells (Figure 2) were transfected 
with TAp73alpha, caspase-2 and/or empty expression vectors, 
and caspase-2 activity was monitored. The enzyme activity of 
caspase-2 (VDVADase activity) was evaluated as the release of 
AMC from the substrate Ac-VDVAD-AMC (Ac-Val-Asp-Val-
Ala-Asp-7-amino-4-methylcoumarin). The data represents three 
independent experiments. 
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encoding TAp73alpha, and/or caspase-2. Twenty-four 
hours post-transfection, cells were stained with TMRE and 
then assessed for the loss of mitochondrial transmembrane 
potential (TMRE-negative cells) by scoring EGFP 
expressing cells by FACS analysis. In NCI-H82 cells, 
caspase-2 over-expression provoked a noteworthy 
loss  of  mitochondrial  transmembrane  potential  (37.8% 
cells with loss of mitochondrial membrane potential), 
whereas TAp73alpha expression showed limited effect 
as compared to control (15% vs. 12.3% cells with loss of 
mitochondrial membrane potential) (Fig. 3). Interestingly, 
caspase-2 induced loss of mitochondrial transmembrane 
potential was reduced when cells were co-transfected 
with TAp73alpha (from 37.8% to 23.7% cells with loss 
of mitochondrial membrane potential) (Fig. 3). Altogether 
these data indicate that TAp73alpha inhibits the caspase-2 
induced loss of mitochondrial transmembrane potential in 
SCLC NCI-H82 cells. 
TAp73alpha counteracts caspase-2 induced Bax 
activation in SCLC NCI-H82 cells
It has previously been shown that caspase-2 is 
essential for the integration of cytosolic Bax into the outer 
mitochondrial membrane, an event that is important for 
subsequent activation of Bax [46]. We have previously 
shown that TAp73alpha is able to prevent Bax activation 
upon VP16 treatment [22, 44]. Thus, we decided to 
explore whether the protective effect of TAp73alpha 
over-expression on caspase-2 induced apoptosis is due 
to repression of Bax activation. To investigate how 
caspase-2 and TAp73alpha regulate Bax activation, we 
took advantage of the 6A7 anti-Bax antibody, which 
recognizes the membrane-bound active form of Bax 
[47]. NCI-H82 cells were co-transfected with EGFP and 
plasmids encoding TAp73alpha, caspase-2 and/or empty 
expression vectors. Twenty-four hours post-transfection, 
NCI-H82 cells were collected and probed with the 6A7 
anti-Bax antibody and subsequently incubated with Alexa 
Fluor 635-conjugated secondary antibody. The samples 
were  analyzed  for  increased  fluorescence  by  FACS 
to  assess  Bax  activation. As  shown  in  figure  4,  over-
expression of caspase-2 in NCI-H82 cells leads to Bax 
conformational changes (Fig. 4, middle, right histogram). 
Co-expression of TAp73alpha resulted in a decrease of 
caspase-2-induced Bax activation (Fig. 4, bottom, right 
histogram). Taken together, in SCLC NCI-H82 cells, 
TAp73alpha seems to counteract the effect of caspase-2 on 
Bax, and consequently inhibit the mitochondrial cell death 
pathway activated upon Bax conformational changes.
TAp73alpha DBD and SAM domain are required 
for inhibition of caspase-2 induced apoptosis
We previously characterized which domains of 
TAp73alpha are essential for the repression of VP16-
induced apoptosis in SCLC NCI-H82 cells. The DBD and 
the unique carboxyl terminus SAM domain of p73alpha 
were both found to be required for its anti-apoptotic 
function [22]. To detect the domains that were required 
for TAp73alpha inhibitory effect on caspase-2 induced 
apoptosis, NCI-H82 cells were co-transfected with 
EGFP together with either an empty (control) vector or 
plasmids encoding different mutant forms of TAp73alpha 
and/or caspase-2 and apoptosis assay was performed. 
In the context of caspase-2 induced cell death, the 
TAp73alphaDBD mutant construct with a double point 
mutation in the DNA binding domain [48] was not able to 
modulate apoptosis induced by caspase-2 over-expression 
(Fig. 5). The deletion construct of TAp73alpha lacking 
the SAM domain was also unable to inhibit caspase-2 
induced apoptosis (Fig. 5). In fact, over-expression of 
the TAp73alphaSAMdel mutant potentiated caspase-2 
induced apoptosis in NCI-H82 SCLC cells, in a manner 
similar to that of TAp73beta. These data suggest that 
both the DBD and the SAM domain of TAp73alpha are 
involved in the inhibition of caspase-2 induced cell death.
DISCUSSION
Although both TAp73alpha and TAp73beta 
can induce cell cycle arrest and apoptosis upon drug 
treatment, TAp73alpha expression is increased in a range 
of tumours and has been shown to confer resistance of 
Figure 3: TAp73alpha prevents caspase-2 induced 
mitochondrial dysfunction in SCLC NCI-H82 cells. 
SCLC NCI-H82 cells (Figure 3) were co-transfected with 
TAp73alpha, caspase-2 and/or empty expression vectors. 
Twenty-four hours post-transfection, cells were stained with 
TMRE and loss of mitochondrial trans-membrane potential 
(TMRE-negative cells) was assayed by scoring of EGFP 
transfected cells without TMRE by FACS analysis. Images are 
representatives of three independent experiments.
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some tumour cells towards drug-treatment [22, 44, 49]. 
Previously, we have shown that TAp73alpha can repress 
drug-induced  apoptosis  in  a  cell-type  specific  manner. 
We demonstrated this effect to be exerted upstream of 
the mitochondria, at the level of Bax activation [22, 44]. 
Here, we provide an additional mechanism in support 
of the anti-apoptotic effect of TAp73alpha. Caspase-2 
activation occurs rapidly in response to a wide range of 
death stimuli and is associated with Bax activation and 
mitochondrial dysfunction, suggesting that it may have a 
general role in apoptosis [40-42]. In this study we show 
that the TAp73alpha, but not the TAp73beta isoform, is 
able to repress caspase-2 induced cell death in SCLC 
NCI-H82 cells. In these cells, we found that TAp73alpha 
inhibit caspase-2 enzymatic activity and thereby prevent 
caspase-2 induced Bax activation and subsequent loss of 
mitochondrial transmembrane potential.
Some of the functional differences between TAp73 
isoforms, e.g. TAp73alpha and TAp73beta, are likely to 
be explained by the specific interactions of TAp73alpha 
unique domains, i.e. SAM domain and extreme carboxy-
terminus,  with  other  proteins.  Specific  p63-regulated 
micro-RNAs have been shown to regulate TAp73 levels 
in general [50], but the receptor for activated kinase 
1 (RACK1) only interacts with TAp73alpha carboxy-
terminus, ultimately resulting in reduced transcriptional 
activity and inhibition of TAp73alpha-induced apoptosis 
[51]. Due to its extended carboxy-terminus, TAp73alpha, 
but  not  TAp73beta,  can  be  covalently  modified  by 
SUMO-1. Sumoylation at the COOH-terminal lysine 627 
leads to a more rapid degradation of TAp73alpha by the 
proteasome [52]. Here, we characterized the structure 
requirement for the repressive effect of TAp73alpha on 
caspase-2 induced cell death in SCLC NCI-H82 cells 
and found that the DNA binding domain as well as the 
unique SAM domain of TAp73alpha are required for the 
suppression of caspase-2 induced cell death. 
Recent investigations suggests that caspase-2 may 
have additional roles in DNA damage response and cell 
cycle regulation [23]. Indeed, several recent publications 
Figure 4: TAp73alpha counteracts caspase-2 induced Bax activation in SCLC NCI-H82 cells. SCLC NCI-H82 cells (Figure 
4) were co-transfected with EGFP and plasmids encoding TAp73alpha, caspase-2 and/or empty expression vectors. Twenty-four hours 
post-transfection, SCLC NCI-H82 cells were collected, fixed in 4% PFA and incubated with the 6A7 anti-Bax antibody at 4°C, overnight, 
followed by secondary Alexa Fluor 635-conjugated antibody. For each sample 10,000 cells were sorted for green (EGFP) fluorescence 
using BD LSR II flow cytometer, and assessed for intensity of active Bax staining.
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provide evidences that caspase-2 can function as a 
regulator of cell cycle checkpoints, and in DNA repair 
[53-54]. 
Furthermore, in an E mu-Myc mouse model of 
lymphomagenesis, loss of caspase-2 results in an increased 
ability of cells to acquire a transformed phenotype and 
become malignant, indicating that caspase-2 functions as 
a tumour suppressor [55]. Whether TAp73alpha can also 
alter these additional caspase-2 functions remain to be 
established. Nevertheless, considering that TAp73alpha 
overexpression is associated with resistance to treatment 
with  DNA-damaging agents in human ovarian cancer 
and SCLC cell lines [22, 49], this possibility cannot be 
excluded. 
As mentioned earlier, caspases-3, -7 and -9 are 
susceptible to inhibition by members of the inhibitors 
of apoptosis (IAP) family, and with the exception of 
some baculoviral proteins (e.g. p35 and p49), no natural 
caspase-2 inhibitors have been reported. Here we report 
that TAp73alpha, a member of p53 family of proteins, 
inhibits caspase-2 enzymatic activity and protects SCLC 
NCI-H82 cells from caspase-2 mediated mitochondrial 
cell death. Moreover, we conclude that the anti-apoptotic 
effect of TAp73alpha requires the presence of a functional 
DNA binding domain and SAM domain, and operates 
at the initiation phase of apoptosis, upstream of Bax 
activation and loss of the mitochondrial transmembrane 
potential. Caspase-2 activation occurs rapidly in response 
to a range of death stimuli and is associated with both 
Bax activation and mitochondrial dysfunction, suggesting 
that it may have a general role in apoptosis [40-42]. Thus, 
the ability of TAp73alpha to inhibit caspase-2 induced 
cell death and its up-regulation in certain tumour types 
[15-20, 56] uncover new potential oncogenic activities 
for this protein. NF-kappaB, a transcription factor which 
exhibits both pro- and anti-apoptotic characters [57], 
was suggested to have a Jekyll and Hyde behaviour in a 
cell context dependent manner [58]. This behaviour also 
seems to apply to TAp73alpha, a behaviour we obviously 
need to understand to make the most use of drugs and 
cancer treatments in general.
MATERIALS AND METHODS
Plasmids
Expression vectors encoding human TAp73alpha and 
TAp73beta were kind gifts from Dr. G. Melino and have 
been described [59-60]. The TAp73alphaDBD mutant 
having amino acid substitutions at positions 268 and 300 
on the DNA-binding domain was a generous gift from 
Dr. S. Deb [48]. Carboxyl-terminus deleted TAp73alpha 
mutant lacking the SAM domain, TAp73alphaSAMdel 
was a kind gift from Dr M. Hijikata [61]. Dr. S. Kumar 
kindly provided us with plasmid encoding caspase-2 [35]. 
Enhanced green fluorescent protein (EGFP) plasmid was 
from Clontech. The empty pcDNA-3.1 vector was used as 
control (mock).
Cell Culture, transfection and treatments
The human small cell lung carcinoma NCI-H82 
(ATCC HTB-175) cell line was used in this study. The 
NCI-H82 cells produce an abnormally sized p53 mRNA 
Figure 5: The DNA binding domain and SAM domain are required for TAp73alpha inhibition of caspase-2 induced 
apoptosis. SCLC NCI-H82 cells (Figure 5) were co-transfected with EGFP together with either an empty (control) vector, TAp73alpha 
or plasmids encoding different mutant forms of TAp73alpha (DBDmutp73alpha/p73alphaSAMdel), and/or caspase-2. Twenty-four hours 
post-transfection, cells were fixed, stained with Hoechst and scored under a fluorescence microscope as percentage of EGFP expressing 
cells displaying condensed or fragmented nuclei. Three hundred EGFP transfected cells were analyzed and each experiment was repeated 
three times. Figures are mean + SD of three independent experiments, where *p <0.05.
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(3.7 kb) and do not show detectable levels of p53 protein. 
Cells  were  cultured  at  37°C,  5%  CO2 in RPMI 1640 
medium,  supplemented  with  10% heat-inactivated fetal 
calf serum, 2 mM L-glutamine, penicillin (100 units/
ml), and streptomycin (100 mg/ml). Twenty-four hours 
after setting in culture dishes with fresh medium, cells 
were transfected using Lipofectamine 2000 (Invitrogen) 
according to the manufacturer’s protocol. If not stated 
otherwise, the co-transfection ratio of TAp73alpha to 
caspase-2 was always kept at 2:1. When indicated, H82 
cells were treated with 10 uM etoposide (VP16; Bristol-
Myers) for 24 hours. The cell density was kept at levels 
allowing exponential growth.
Flow cytometric analysis of Bax activation
Bax-associated conformational changes were 
assessed as previously described [44]. Briefly, one day 
after co-transfection of EGFP and plasmids encoding 
TAp73alpha, caspase-2 and/or empty (control) vector, 
H82 cells were harvested, fixed in 4% PFA and blocked/
permeabilized in PBS with 10 mM HEPES, 0.3% Triton 
X-100 and 3% BSA. Subsequently, cells were incubated 
with an antibody recognizing N-terminal epitopes of Bax 
(clone 6A7; BD Biosciences) at 4°C, overnight, followed 
by secondary Alexa Fluor 635-conjugated antibody 
(Invitrogen) at room temperature, for 30 minutes. Cells 
were re-suspended in PBS. For each sample 10,000 cells 
were  sorted  for  green  (EGFP)  fluorescence  using  BD 
LSR II flow cytometer, and assessed for intensity of Bax 
staining using FlowJo software version 9.4.3 (Tree Star, 
Ashland, OR).
Flow cytometric analysis of mitochondrial 
depolarization 
Cytofluorometric  analysis  of  mitochondrial 
membrane depolarization was assessed by uptake of 
tetramethylrhodamine ethyl esters (TMRE; Molecular 
Probes/Invitrogen),  a  lipophilic,  cationic  fluorochrome 
dye that is only taken up by mitochondria having an intact 
electrochemical gradient. H82 cells were co-transfected 
with EGFP and plasmids encoding TAp73alpha, caspase-2 
and/or empty (control) vector. Following TMRE exposure 
(added 30 min before harvesting to a final concentration 
of 25 nM), cells were centrifuged and re-suspended in 
TMRE- containing PBS. Analysis was carried out on 
10,000 gated EGFP-expressing cells using a FACSCalibur 
flow cytometer equipped with CellQuest software (BD 
Biosciences).
Detection of Apoptosis
H82 cells were co-transfected with EGFP and 
plasmids encoding TAp73 isoforms/mutants, caspase-2 
and/or empty (control) vector. One day after transfections, 
cells  were  fixed  with  4%  PFA,  and  nuclei  were 
counterstained using Hoechst 33342 (Molecular Probes/
Invitrogen). Number of apoptotic cells was scored under 
a  fluorescence  microscope  (Zeiss  Axioplan  2  Imaging 
microscope system) by assessing the percentage of EGFP-
positive cells displaying apoptotic nuclear morphology 
(fragmented or condensed nuclei).
Measurement of caspase-2 activity
H82 cells were transfected with TAp73alpha, 
caspase-2 and/or empty expression vectors. After 24 
hours of transfection, cells were collected, washed in PBS 
and pellets frozen in eppendorf tubes on liquid nitrogen. 
After thawing on ice, pellets were re-suspended in 50 ul 
PBS, and 25 ul of cell lysate transferred to a microtiter 
plate together with 50 uL of caspase-2 assay buffer (0.1M 
MES pH 6.5, 0.0001% NP40, 10% PEG, 0.1% CHAPS, 
5 mM DTT, 50 uM Ac-VDVAD-AMC). Cleavage of 
the  fluorogenic  peptide  substrate,  Ac-VDVAD-AMC 
(Ac-Val-Asp-Val-Ala-Asp-7-amino-4-methylcoumarin) 
was monitored by liberation of AMC in a Fluoroscan 
II plate reader (Thermo Electron Co., Waltham, MA, 
USA) by using 355 nM excitation and 460 nM emission 
wavelengths. Data from triplicate samples were used in 
each experiment. 
Statistical analysis
Statistical analyses were performed using two-
tailed, paired students t-test, where ***p-value <0.001, 
**p-value <0.01 and *p-value <0.05. 
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